377 related articles for article (PubMed ID: 28881341)
1. The Association of Combined Total Kidney and Liver Volume with Pain and Gastrointestinal Symptoms in Patients with Later Stage Autosomal Dominant Polycystic Kidney Disease.
D'Agnolo HMA; Casteleijn NF; Gevers TJG; de Fijter H; van Gastel MDA; Messchendorp AL; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JFM; Zietse R; Gansevoort RT; Drenth JPH
Am J Nephrol; 2017; 46(3):239-248. PubMed ID: 28881341
[TBL] [Abstract][Full Text] [Related]
2. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
van Aerts RMM; Kievit W; D'Agnolo HMA; Blijdorp CJ; Casteleijn NF; Dekker SEI; de Fijter JW; van Gastel M; Gevers TJ; van de Laarschot LFM; Lantinga MA; Losekoot M; Meijer E; Messchendorp AL; Neijenhuis MK; Pena MJ; Peters DJM; Salih M; Soonawala D; Spithoven EM; Visser FW; Wetzels JF; Zietse R; Gansevoort RT; Drenth JPH;
Gastroenterology; 2019 Aug; 157(2):481-491.e7. PubMed ID: 31022403
[TBL] [Abstract][Full Text] [Related]
3. Volume Progression and Imaging Classification of Polycystic Liver in Early Autosomal Dominant Polycystic Kidney Disease.
Bae KT; Tao C; Feldman R; Yu ASL; Torres VE; Perrone RD; Chapman AB; Brosnahan G; Steinman TI; Braun WE; Mrug M; Bennett WM; Harris PC; Srivastava A; Landsittel DP; Abebe KZ;
Clin J Am Soc Nephrol; 2022 Mar; 17(3):374-384. PubMed ID: 35217526
[TBL] [Abstract][Full Text] [Related]
4. Severity in polycystic liver disease is associated with aetiology and female gender: Results of the International PLD Registry.
van Aerts RMM; Kievit W; de Jong ME; Ahn C; Bañales JM; Reiterová J; Nevens F; Drenth JPH
Liver Int; 2019 Mar; 39(3):575-582. PubMed ID: 30225933
[TBL] [Abstract][Full Text] [Related]
5. Total kidney and liver volume is a major risk factor for malnutrition in ambulatory patients with autosomal dominant polycystic kidney disease.
Ryu H; Kim H; Park HC; Kim H; Cho EJ; Lee KB; Chung W; Oh KH; Cho JY; Hwang YH; Ahn C
BMC Nephrol; 2017 Jan; 18(1):22. PubMed ID: 28088190
[TBL] [Abstract][Full Text] [Related]
6. Effect of genotype on the severity and volume progression of polycystic liver disease in autosomal dominant polycystic kidney disease.
Chebib FT; Jung Y; Heyer CM; Irazabal MV; Hogan MC; Harris PC; Torres VE; El-Zoghby ZM
Nephrol Dial Transplant; 2016 Jun; 31(6):952-60. PubMed ID: 26932689
[TBL] [Abstract][Full Text] [Related]
7. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
Gevers TJ; Hol JC; Monshouwer R; Dekker HM; Wetzels JF; Drenth JP
Liver Int; 2015 May; 35(5):1607-14. PubMed ID: 25369108
[TBL] [Abstract][Full Text] [Related]
8. Image texture features predict renal function decline in patients with autosomal dominant polycystic kidney disease.
Kline TL; Korfiatis P; Edwards ME; Bae KT; Yu A; Chapman AB; Mrug M; Grantham JJ; Landsittel D; Bennett WM; King BF; Harris PC; Torres VE; Erickson BJ;
Kidney Int; 2017 Nov; 92(5):1206-1216. PubMed ID: 28532709
[TBL] [Abstract][Full Text] [Related]
9. Baseline total kidney volume and the rate of kidney growth are associated with chronic kidney disease progression in Autosomal Dominant Polycystic Kidney Disease.
Yu ASL; Shen C; Landsittel DP; Harris PC; Torres VE; Mrug M; Bae KT; Grantham JJ; Rahbari-Oskoui FF; Flessner MF; Bennett WM; Chapman AB;
Kidney Int; 2018 Mar; 93(3):691-699. PubMed ID: 29290310
[TBL] [Abstract][Full Text] [Related]
10. Cisterna chyli in autosomal dominant polycystic kidney disease.
Thimmappa ND; Blumenfeld JD; Cerilles MA; Dunning A; Donahue SL; Bobb WO; Zhang HL; Prince MR
J Magn Reson Imaging; 2015 Jan; 41(1):142-8. PubMed ID: 24470398
[TBL] [Abstract][Full Text] [Related]
11. The association of serum angiogenic growth factors with renal structure and function in patients with adult autosomal dominant polycystic kidney disease.
Coban M; Inci A
Int Urol Nephrol; 2018 Jul; 50(7):1293-1300. PubMed ID: 29654395
[TBL] [Abstract][Full Text] [Related]
12. Renal structure in early autosomal-dominant polycystic kidney disease (ADPKD): The Consortium for Radiologic Imaging Studies of Polycystic Kidney Disease (CRISP) cohort.
Chapman AB; Guay-Woodford LM; Grantham JJ; Torres VE; Bae KT; Baumgarten DA; Kenney PJ; King BF; Glockner JF; Wetzel LH; Brummer ME; O'Neill WC; Robbin ML; Bennett WM; Klahr S; Hirschman GH; Kimmel PL; Thompson PA; Miller JP;
Kidney Int; 2003 Sep; 64(3):1035-45. PubMed ID: 12911554
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Outcomes in Patients with Very-Early Onset Autosomal Dominant Polycystic Kidney Disease.
Nowak KL; Cadnapaphornchai MA; Chonchol MB; Schrier RW; Gitomer B
Am J Nephrol; 2016; 44(3):171-8. PubMed ID: 27548646
[TBL] [Abstract][Full Text] [Related]
14. Multiple urinary tract infections are associated with genotype and phenotype in adult polycystic kidney disease.
Eroglu E; Kocyigit I; Cetin M; Zararsiz G; Imamoglu H; Bayramov R; Tastan S; Sipahioglu MH; Tokgoz B; Oymak O
Clin Exp Nephrol; 2019 Oct; 23(10):1188-1195. PubMed ID: 31165946
[TBL] [Abstract][Full Text] [Related]
15. Volume regression of native polycystic kidneys after renal transplantation.
Jung Y; Irazabal MV; Chebib FT; Harris PC; Dean PG; Prieto M; Cosio FG; El-Zoghby ZM; Torres VE
Nephrol Dial Transplant; 2016 Jan; 31(1):73-9. PubMed ID: 26044834
[TBL] [Abstract][Full Text] [Related]
16. A Randomized Clinical Trial of Metformin to Treat Autosomal Dominant Polycystic Kidney Disease.
Seliger SL; Abebe KZ; Hallows KR; Miskulin DC; Perrone RD; Watnick T; Bae KT
Am J Nephrol; 2018; 47(5):352-360. PubMed ID: 29779024
[TBL] [Abstract][Full Text] [Related]
17. Hemorrhagic Cysts and Other MR Biomarkers for Predicting Renal Dysfunction Progression in Autosomal Dominant Polycystic Kidney Disease.
Riyahi S; Dev H; Blumenfeld JD; Rennert H; Yin X; Attari H; Barash I; Chicos I; Bobb W; Donahue S; Prince MR
J Magn Reson Imaging; 2021 Feb; 53(2):564-576. PubMed ID: 32969110
[TBL] [Abstract][Full Text] [Related]
18. Relationship of urinary endothelin-1 with estimated glomerular filtration rate in autosomal dominant polycystic kidney disease: a pilot cross-sectional analysis.
Raina R; Lou L; Berger B; Vogt B; Do AS; Cunningham R; Vasavada P; Herrmann K; Dell K; Simonson M
BMC Nephrol; 2016 Feb; 17():22. PubMed ID: 26923419
[TBL] [Abstract][Full Text] [Related]
19. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
Gevers TJ; Chrispijn M; Wetzels JF; Drenth JP
BMC Nephrol; 2012 Apr; 13():17. PubMed ID: 22475206
[TBL] [Abstract][Full Text] [Related]
20. Health-related quality of life in patients with autosomal dominant polycystic kidney disease and CKD stages 1-4: a cross-sectional study.
Miskulin DC; Abebe KZ; Chapman AB; Perrone RD; Steinman TI; Torres VE; Bae KT; Braun W; Winklhofer FT; Hogan MC; Rahbari-Oskoui F; Moore CG; Flessner MF; Schrier RW;
Am J Kidney Dis; 2014 Feb; 63(2):214-26. PubMed ID: 24183837
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
